Jeon Hwa-seong's Startup Morning Coffee #1213: AI Personalized Nutrition

Every day at 8:40 AM, 'Startup Morning Coffee,' which ushers in the vibrant morning of the startup ecosystem, goes live to viewers on the 'Jeon Hwa-sung's CNTV' channel, hosted by CEO Jeon Hwa-sung. This program deeply illuminates the core competencies and market potential of promising startups, establishing itself as an indispensable information platform for those interested in startups, thanks to interactive communication through real-time comments. One of the companies recently covered in depth by this program is 'BioBytes,' a specialized biotech company striving to solve key challenges of an aging society. BioBytes defines the lack of 'muscle quality,' beyond mere muscle mass reduction, as the essence of sarcopenia, and is dedicated to developing diagnostic and therapeutic solutions for this disease. In particular, it is focusing on AI-based diagnostic software and the discovery of biomarkers for new drug development, emerging as a leader in this field. The founding team consists of multidisciplinary experts including faculty from Severance Hospital, specializing in public health, pharmacy, and bioinformatics, and is currently accelerating its growth through CNT Tech's 'Korea Industrial Complex Corporation Kicks-up Challenge' program. BioBytes' core competitiveness lies in its AI-based precision diagnostic solutions and its market penetration strategy utilizing extensive patient cohort data. A prime example of this is 'Mutest,' a high-precision AI diagnostic solution. This software predicts sarcopenia with an impressive 95% accuracy using only basic patient data such as interviews, medical history, and health check-up records. Furthermore, it enhances diagnostic depth by precisely analyzing motor skills like walking speed and balance using motion analysis technology. Currently, 'Mutest' is smoothly proceeding with clinical trials for the expansion of its Class 2 diagnostic module, aiming for successful approval in the first half of next year, thus raising expectations for commercialization. CEO Jeon Hwa-sung emphasized that BioBytes simultaneously possesses three core competencies for solving sarcopenia, a serious problem in an aging society: 'AI precision diagnosis,' 'large-scale patient data cohorts,' and 'integrated omics analysis.' Based on these unique capabilities, he predicted that while maximizing diagnostic efficiency, the company would also contribute to the development of fundamental therapeutics through innovative biomarker technology. Consequently, he assessed that BioBytes possesses sufficient potential to rapidly grow into a unique company leading the diagnosis-to-treatment linkage system in the field of sarcopenia.